Ibrance CAS 571190-30-2 Palbociclib

Model: MOS-new5
Place of Origin: Zhejiang,China (Mainland)
Name: Ibrance
Name 1: Palbociclib
CAS: 571190-30-2
Molecular formula: C24H29N7O2
Molecular weight: 447.54


skype basketAdd to Basket  Edit

Share |

Product Description

Payment & Shipping Terms Supply Capacity
Trade Term:FOB,CIF,DDPProduction Capacity:1kg/year
Payment Terms:T/T, WUPacking:according to the...
Min. Order:1 GramDelivery Date:7 days
Means of Transport:Ocean, Air, Land


CAS: 571190-30-2

Palbociclib, a new breast cancer drug developed by Pfizer in the United States, is marketed as IBRANCE, an oral cyclin-dependent kinase (CDKs) 4 and 6 inhibitor, the first cyclin-dependent kinase 4/6 (cdk4/6) inhibitor approved by the us FDA. CDKs4 and 6 are key regulators of cell cycle and can trigger cell cycle progression. IBRANCE is indicated in the United States for the combination of letrozole for the treatment of estrogen receptor-positive, and human epidermal growth factor receptor-negative (ER+/ her2-negative) postmenopausal advanced breast cancer patients, as an initial endocrine-based regimen for the treatment of metastatic diseases.

We can customize according to customer's requirement

if you have any question pls mail us or call us

Category: Hot anti-cancer medicines

Related Category: Pharmaceutical Intermediates  Customized Pharmaceutical API  Other Pharmaceutical API  Veterinary Medicine API  Diagnostic Agents API 

Offline Showroom in USA
QR Code